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SUMMARY – High stroma proportion appears to be a very important prognostic factor in 
esophageal and breast cancer. Previous researches have shown that it might have a similar eff ect on 
colorectal cancer. Th e aim of this study was to determine whether tumor stroma proportion infl uenced 
patient survival. Th is retrospective study included 236 patients with colorectal cancer having under-
gone surgery in 2006 and 2007 at Osijek University Hospital Center. Location with the highest 
stroma proportion at the site of deepest tumor invasion was determined. Patients were divided into the 
groups with high stroma proportion (>50%) and low stroma proportion (≤50%). Stroma proportion 
showed a statistically signifi cant correlation with tumor stage. Kaplan-Meier survival curves yielded a 
statistically signifi cant diff erence in patient overall survival (Cox ph model p=0.016) and progression-
free survival (Cox ph model, p=0.0188) according to stroma proportion. Study results showed a statis-
tically signifi cantly shorter overall survival and progression-free survival in patients with high stroma 
proportion.
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Introduction
Colorectal cancer is a huge health issue. Unfortu-
nately, the incidence and mortality of colorectal cancer 
have been growing in Croatia as opposed to developed 
countries1,2. Postoperative patient treatment poses a 
special kind of problem3. Patients with disease stage I 
are not indicated any additional therapy after the sur-
gery4. Patients with disease stage III are indicated 
 additional chemotherapy after the surgery5. Patients 
with disease stage II present a special problem; about 
25% of these patients have disease recurrence within 5 
years6. Th e infl uence of additional chemotherapy on 
patients with disease stage II has been the basis for 
several clinical trials. Results of a meta-analysis of 5 
trials have shown patients with disease stage III to 
benefi t most from additional chemotherapy6-8. How-
ever, new results of 12 controlled clinical studies from 
1988 to 2010 have shown signifi cant benefi t of addi-
tional chemotherapy in patients with disease stage II9.
On the other hand, the Quasar Collaborative 
Group study6 has shown little benefi t of chemotherapy 
compared to no chemotherapy in patients with disease 
stage II. Th e benefi t was about 3.6%. Th is percentage is 
below the accepted level of 5% and therefore chemo-
therapy for the entire stage II group is not advised.
Numerous studies have shown which parameters 
mean worse prognosis for patients with colorectal can-
cer. Th ese parameters include evaluation of less than 
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12 lymph nodes11, lymphovascular or perineural inva-
sion, poor tumor diff erentiation, younger age, close 
resection lines, and perforation during or after sur-
gery4,12. Based on these parameters, it is decided 
whether patients will receive chemotherapy.
In practice, we often encounter patients that have 
good prognostic factors but their metastatic disease 
develops very soon. Patients with a small primary tu-
mor sometimes have a metastatic disease at the begin-
ning.
A simple concept according to which tumor pro-
gression depends only on the intrinsic ability of tumor 
cells has been ever more widely rejected in the last 
couple of years. Th is points to the fact that tumor pro-
gression is the result of interaction between tumor and 
stroma cells, as well as the surrounding stroma cells13,14. 
Th e researches known so far have confi rmed that tu-
mor stroma infl uences tumor growth, angiogenesis 
and  dissemination. It is believed that stroma induces 
tumorigenesis by various mechanisms such as remod-
eling of extracellular matrix, suppression of immune 
response and motility, as well as aggressiveness of can-
cer cells15-17.
It has been evident that stroma has a prognostic 
value in esophageal cancer18,19 and breast cancer20, es-
pecially triple negative breast cancer21,22.
Using simple modifi ed methodology, we tried to 
determine the impact of stroma proportion on pro-
gression-free survival and overall survival. We also 
tried to determine the association of tumor stroma 
Fig. 1. Determination of stroma proportion using computer Adobe Photoshop CS2 when tumor is covering whole photo.
Fig. 2. Determination of stroma proportion using computer program Adobe Photoshop CS2 when tumor is not covering 
whole photo.
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with previously known histopathologic features of the 
tumor. We tried to use simple, innovative methodolo-
gy to quantifi y stroma proportion.
Patients and Methods
Our study included patients having undergone 
colorectal cancer surgery in 2006 and 2007 at Clinical 
Department of Surgery, and then treated or monitored 
at Clinical Department of Oncology, Osijek Univer-
sity Hospital Center. From analysis were excluded pa-
tients that had only colonoscopy and no surgery, and 
patients that died within a month after surgery (peri-
operative mortality). Patients that had received neoad-
juvant oncologic therapy (neoadjuvant chemoradio-
therapy for rectal cancer), patients with a history of 
malignant tumor and those with two synchronous co-
lon cancers were not included in analysis. Considering 
patients having undergone surgery at Clinical Depart-
ment of Surgery but not treated at Clinical Depart-
ment of Oncology, Osijek University Hospital Center, 
only data that could be read from histopathologic 
fi ndings kept at Department of Pathology, Osijek 
University Hospital Center were included in analysis. 
Department of Pathology provided data on histopath-
ologic features of the tumor (tumor size, tumor stage, 
number of lymph nodes removed, number of lymph 
nodes with tumor cells, tumor grade of diff erentiation, 
presence of lymphovascular or perineural invasion, tu-
mor distance from resecting edge, and whether the 
 patient underwent surgery for metastases). Medical 
history of patients provided by Clinical Department of 
Oncology included data on patient sex and age, date of 
surgery, type of surgery, metastases and their locations, 
and adjuvant treatment of patients. We also received 
information on the date of disease progression, date of 
the last examination, and date of death for the patients 
that died.
Our pathologist identifi ed the area of deepest tu-
mor invasion with highest stroma proportion. Th en he 
took a photo of this area at 20X magnifi cation using 
Bx41 Olympus microscope with Olympus C-4040 
digital camera. Using a computer program Adobe 
Photoshop CS2, we manually determined stroma area 
using green color (Fig. 1). Th en we calculated the pro-
portion of stroma based on the number of pixels (the 
number of green pixels/total image pixels (241968)). 
On most photos, tumor covered the whole photo, but 
on some photos it was not possible due to the size of 
the tumor (Fig. 2). In this case, the number of yellow 
colored points was subtracted from the whole number 
of picture pixels. Th e areas of necrosis were yellow col-
ored, while mucus that was part of the tumor was not 
yellow but remained colorless. Tumor stroma propor-
tion was calculated afterwards. Th e cut-off  point be-
tween high and low stroma proportion was set at 50%.
Statistics
Categorical data were presented as absolute and 
relative frequencies. Numerical data were presented as 
mean and standard deviation and, if necessary, with 
median and quartiles and other standard measures of 
descriptive statistics. Analysis of variance was used to 
determine relationship between stroma proportion 
and other histopathologic characteristics. Overall sur-
vival and progression-free survival were estimated by 
Kaplan-Meier survival curves. Diff erences in overall 
survival and progression-free survival were tested us-
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ing the Cox ph model, likelihood ratio test, and log-
rank test. Th e level of signifi cance was set at 0.05.
On statistical analysis, was used STATISTICA64 
(version 11, StatSoft.Inc., Tulsa, OK, USA) statistical 
program and software package R, library “OIsurv” for 
survival analysis23.
Results
Th e analysis included 236 patients with all tumor 
stages, mean age 64.22 (standard deviation (SD) 
11.46) years. Th ey all had undergone surgery at Cinical 
Department of Surgery, Osijek University Hospital 
Center, and 206 of them were then treated and fol-
lowed up at Clinical Department of Oncology, Osijek 
University Hospital Center. Demographic characteris-
tics of patients and histopathologic characteristics of 
tumors are shown in Table 1.
We analyzed correlation between tumor stroma, 
pathologic characteristics of tumor and survival. Stro-
ma proportion was determined in all study patients. 
Th e mean value of tumor stroma was 44.23% (SD 
12.10%). Analysis of variance confi rmed a statistically 
signifi cant diff erence in stroma proportion due to tu-
mor T stage (p=0.002) and N stage (p=0.038).
Relationship of the median overall survival and 
histopathologic characteristics of tumor is presented in 
Table 2. Th ere was no statistically signifi cant diff erence 
in overall survival according to tumor localization, 
 tumor diff erentiation, and perineural and lymphovas-
cular invasion.
Relationship between progression-free survival and 
tumor characteristics is presented in Table 3. Th ere was 
a statistically signifi cant diff erence in progression-free 
survival among all characteristics except for tumor dif-
ferentiation.
Th e Cox proportional hazards methodology of 
modeling with a single predictor was used to analyze 




CI (95%) p value‡
Localization Right NA 2380-NA 0.052
Left 1717 1330-2452
T stage T2 NA NA-NA 0.004
T3 1948 1367-2452
T4 892 447-NA
N stage N0 NA 2397-NA <0.001
N1 2155 1431-NA
N2 810 560-1408
M stage M0 3287 2380-NA <0.001
M1 447 330-671














Yes 1338 810-NA 0.059
No 2301 1431-NA
NA = not applicable; OS = overall survival; ‡log-rank test




CI (95%) p value‡
Localization Right NA 896-NA 0.023
Left 715 583-1220
T stage T2 NA 2553-NA 0.049
T3 784 655-1710
T4 442 258-NA
N stage N0 NA NA-NA <0.001
N1 1184 722-NA
N2 405 316-595
M stage M0 2474 1385-NA <0.001
M1 241 168-334














Yes 588 442-1844 0.029
No 1385 742-NA
NA = not applicable; PFS = progression-free survival; ‡log rank test
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correlation between stroma proportion and patient 
survival. Th e likelihood ratio test revealed a statisti-
cally signifi cant role of tumor stroma proportion in the 
models of overall survival (p=0.016) and progression-
free survival (p=0.019).
Th e Kaplan-Meier survival curves of overall sur-
vival and tumor stroma proportion are shown in Fig-
ure 3, and Kaplan-Meier survival curves of progres-
sion-free survival and tumor stroma proportion in 
Figure 4.
Discussion
Th e parameters associated with worse prognosis in 
patients with colorectal cancer include evaluation of 
less than 12 lymph nodes10, lymphovascular or peri-
neural invasion, poor tumor diff erentiation, younger 
age, close resection lines, and perforation during or af-
ter surgery3,11. Th ese parameters are not good enough 
to predict outcome in patients with colorectal cancer. 
We need more and better parameters in clinical prac-
tice.
In recent research, some new parameters have 
emerged that may have a prognostic role in colorectal 
cancer, one of them being the amount of stroma, which 
was fi rst demonstrated as a prognostic factor in breast 
and esophageal cancer17-22. Th e role of stroma propor-
tion, or tumor cell proportion in the prognosis of 
colorectal cancer has been reported in four papers so 
far; they have demonstrated the proportion of stroma 
to be a signifi cant prognostic factor in colorectal can-
cer and the higher proportion of tumor stroma to be 
associated with better patient prognosis24,25,28,29. In 
2007, Mesker et al. showed the carcinoma-stroma ratio 
to be an independent factor for survival as compared 
with lymph node status and tumor stage24. In 2010, 
West et al. proved the smaller cancer cell proportion to 
be an independent prognostic factor for survival in 
colorectal cancer25. In 2012, the VICTOR trial was 
started26,27. Th e authors planned to include 7000 pa-
Fig. 3. Kaplan-Meier curves of overall survival and tumor stroma proportion.
Fig. 4. Kaplan-Meier curves of progression-free survival and tumor stroma proportion.
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tients. Th e purpose of this study was to test whether 
the COX-2 inhibitor rofecoxib could reduce recur-
rence and improve survival when administered in the 
adjuvant setting of colorectal cancer stage II and III. 
Since cardiotoxicity of refecoxib had been established, 
the trial was stopped. Results of this huge trial includ-
ing over 700 patients have confi rmed previous results 
that stroma is an independent prognostic factor in 
colorectal cancer stage II and III28, which was con-
fi rmed in the study conducted by Park et al. in 201429.
Our trial confi rmed diff erence in overall survival 
and progression-free survival. Th is diff erence was sta-
tistically signifi cant, which is consistent with previous 
studies. Previous trials have shown strong heterogene-
ity in tumor cells within the tumor. Th e stroma pro-
portion is not the same throughout the tumor. In 
breast cancer, some studies have shown that tumors 
with a high proportion of tumor cells at the periphery 
of the tumor have better prognosis30, while others re-
port opposite fi ndings when looking at the entire tu-
mor31. In previous trials, researchers used subjective 
methodology where two independent pathologists 
tried to estimate stroma proportion27,28, while Mesker 
et al. used a software that is not available in every hos-
pital24. In our trial, we tried to quantify stroma propor-
tion using a simple, widely accessible methodology. 
Using this methodology, it is simple to determine 
stroma proportion. According to previous trials24,25,28,29 
and the fact that it is impossible to determine stroma 
proportion in the whole tumor, we believe that the area 
with the largest stroma proportion at the site with 
deepest tumor penetration is adequate to analyze and 
set the stroma proportion as a prognostic factor for 
colorectal cancer.
In conclusion, our study showed the importance of 
tumor stroma proportion in determining outcome in 
patients with colorectal cancer. As it is simple to deter-
mine, it could be included as a prognostic parameter in 
the routine histopathologic reports.
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Sažetak
UDIO TURMOSKE STROME KAO LOŠ PROGNOSTIČKI ČIMBENIK 
KOD KARCINOMA DEBELOG CRIJEVA
J. Flam, D. Gugić, M. Benšić, S. Tomić i J. Rajc
Dokazano je da je visok udio strome značajan prognostički čimbenik kod karcinoma jednjaka i karcinoma dojke. Pret-
hodna istraživanja su pokazala da bi isti utjecaj stroma mogla imati i kod kolorektalnog karcinoma. Cilj istraživanja je bio 
utvrditi je li udio tumorske strome povezan s preživljenjem bolesnika s kolorektalnim karcinomom. Provedeno je retrospek-
tivno istraživanje u 236 bolesnika koji su operirani na Klinici za kirurgiju Kliničkoga bolničkog centra Osijek. Određeno je 
područje s najvećim udjelom strome u području najdubljeg prodora tumora. Bolesnici su podijeljeni u dvije skupine: onu s 
visokim udjelom strome (>50%) i onu s niskim udjelom strome (≤50%). Udio tumorske strome bio je statistički značajno 
povezan sa stadijem tumora. Kaplan-Meierova analiza je pokazala statistički značajnu razliku u ukupnom preživljenju (Cox 
ph model p=0,016) i preživljenju do progresije (Cox ph model, p=0,0188) bolesnika u odnosu na udio strome. Rezultati su 
pokazali statistički značajno kraće ukupno preživljenje i preživljenje do progresije bolesti kod bolesnika s visokim udjelom 
strome.
Ključne riječi: Kolorektalni tumori; Stromalne stanice; Preživljavanje; Bolest, napredovanje; Preživljavanje bez znakova 
 bolesti; Prognoza
